GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advaxis Inc (OTCPK:ADXS) » Definitions » Asset Turnover

Advaxis (Advaxis) Asset Turnover : 0.00 (As of Mar. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Advaxis Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Advaxis's Revenue for the three months ended in Mar. 2023 was $0.00 Mil. Advaxis's Total Assets for the quarter that ended in Mar. 2023 was $23.46 Mil. Therefore, Advaxis's Asset Turnover for the quarter that ended in Mar. 2023 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Advaxis's annualized ROE % for the quarter that ended in Mar. 2023 was -176.83%. It is also linked to ROA % through Du Pont Formula. Advaxis's annualized ROA % for the quarter that ended in Mar. 2023 was -125.49%.


Advaxis Asset Turnover Historical Data

The historical data trend for Advaxis's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advaxis Asset Turnover Chart

Advaxis Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.39 0.01 0.08 0.01

Advaxis Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Mar23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.01 - - -

Competitive Comparison of Advaxis's Asset Turnover

For the Biotechnology subindustry, Advaxis's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advaxis's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advaxis's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Advaxis's Asset Turnover falls into.



Advaxis Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Advaxis's Asset Turnover for the fiscal year that ended in Oct. 2022 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Oct. 2022 )/( (Total Assets (A: Oct. 2021 )+Total Assets (A: Oct. 2022 ))/ count )
=0.25/( (46.78+25.93)/ 2 )
=0.25/36.355
=0.01

Advaxis's Asset Turnover for the quarter that ended in Mar. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2023 )/( (Total Assets (Q: Oct. 2022 )+Total Assets (Q: Mar. 2023 ))/ count )
=0.004/( (25.93+20.995)/ 2 )
=0.004/23.4625
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Advaxis  (OTCPK:ADXS) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Advaxis's annulized ROE % for the quarter that ended in Mar. 2023 is

ROE %**(Q: Mar. 2023 )
=Net Income/Total Stockholders Equity
=-29.444/16.651
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-29.444 / 0.016)*(0.016 / 23.4625)*(23.4625/ 16.651)
=Net Margin %*Asset Turnover*Equity Multiplier
=-184025 %*0.0007*1.4091
=ROA %*Equity Multiplier
=-125.49 %*1.4091
=-176.83 %

Note: The Net Income data used here is four times the quarterly (Mar. 2023) net income data. The Revenue data used here is four times the quarterly (Mar. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Advaxis's annulized ROA % for the quarter that ended in Mar. 2023 is

ROA %(Q: Mar. 2023 )
=Net Income/Total Assets
=-29.444/23.4625
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-29.444 / 0.016)*(0.016 / 23.4625)
=Net Margin %*Asset Turnover
=-184025 %*0.0007
=-125.49 %

Note: The Net Income data used here is four times the quarterly (Mar. 2023) net income data. The Revenue data used here is four times the quarterly (Mar. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Advaxis Asset Turnover Related Terms

Thank you for viewing the detailed overview of Advaxis's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Advaxis (Advaxis) Business Description

Traded in Other Exchanges
N/A
Address
9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ, USA, 8540
Advaxis Inc is a clinical-stage biotechnology company operating in the United States. It focuses on the discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate-Specific Antigen (PSA) associated with prostate cancer.
Executives
Roy Golan officer: Chief Financial Officer 24 GOLDA MEIR ST., HOLON L3 5840425
Yuval Cabilly director C/O BIOSIGHT THERAPEUTICS, 4 HASADOT STREET, RAMAT HASHARON L3 4704348
Pini Orbach director C/O BIOSIGHT THERAPEUTICS, 3 HAYARDEN STREET, AIRPORT CITY L3 7019802
Bridget A Martell director C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Israel Biotech Fund Ii, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Israel Biotech Fund Gp Partners Ii, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Murray A Goldberg director 2030 MAIN STREET, SUITE 1500, IRVINE CA 92614
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Vered Bisker-leib director C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Israel Biotech Fund I, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Amoon Growth Fund Limited Partnership 10 percent owner 34 YERUSHALAYIM RD., RAANANA L3 4350110
Israel Biotech Fund Gp Partners, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Yair Chaim Schindel 10 percent owner YERUSHALAYIM ROAD 34, BEIT GAMLA ENTRANCE B, RA'ANANA L3 4350110
I.b.f. Management Ltd. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Igor Gitelman officer: Chief Accounting Officer 201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070

Advaxis (Advaxis) Headlines

From GuruFocus

Advaxis, Inc. Announces 1-for-80 Reverse Stock Split

By GuruFocusNews GuruFocusNews 06-03-2022

Advaxis and Ayala Pharmaceuticals Complete Merger

By Stock market mentor Stock market mentor 01-19-2023